< Retour au portfolio

Xagenic was a molecular diagnostics company based in Toronto, Canada. The company was developing a fully automated platform designed to deliver lab-quality results in 20 minutes, enabling rapid, on-demand testing at the point of care. Their proprietary technology utilized nanostructured microelectrodes for direct detection of nucleic acids without the need for sample extraction or enzymes.

Spécialité

Diagnostics

Nom du fonds

CTI LSF I

Position

Co-Lead

Conseil

Director

Date d'investissement

January 24, 2012

Détail de la sortie

Liquidated in 2018

Ronde de la série initiale

Series A

Thèse d'investissement

Xagenics had the potential to decentralize molecular diagnostics, enabling clinicians to make immediate treatment decisions during patient consultations

les actualités

April 19, 2016

Xagenic readies X1 molecular diagnostic beta trials

Lire

July 14, 2014

Xagenic Announces Second Closing of $25.5M Series B Financing

Lire

November 10, 2016

Toronto’s Xagenic Inc. completes successful beta testing of X1 diagnostic system

Lire
Lire les actualités